Abstract
Long-term glucocorticoid (GC) therapy induces glucocorticoid-induced osteoporosis (GIOP) and its associated fractures. Most specialty organizations recommend bisphosphonates as first-line therapies based only on bone mineral density efficacy data. Effective treatment of GIOP based on head-to-head trials with fracture endpoint has not yet been established. The pathophysiologic mechanisms of GIOP that lead to the detrimental effects on bone are not yet fully elucidated. Although GCs in an early and transitory period promote osteoclastic activity, in the current paper, we outline why GIOP is in fact a disease of the bone formation and then provide the rationale for the use of bone-forming agents as first-line therapy for patients with high fracture risk in GIOP.
Similar content being viewed by others
References
Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids in the United Kingdom. QJM Mon J Assoc Physicians 93:105–111
Fardet L, Petersen I, Nazareth I (2015) Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study. Medicine (Baltimore) 94:e647. https://doi.org/10.1097/MD.0000000000000647
Van Staa TP, Leufkens HGM, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000. https://doi.org/10.1359/jbmr.2000.15.6.993
Balasubramanian WSW, Adler RA et al (2016) Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int 27:3239–3249. https://doi.org/10.1007/s00198-016-3646-z
Overman RA, Yeh J-Y, Deal CL (2013) Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res 65:294–298. https://doi.org/10.1002/acr.21796
Seibel MJ, Cooper MS, Zhou H (2013) Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 1:59–70. https://doi.org/10.1016/S2213-8587(13)70045-7
Van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229. https://doi.org/10.1002/art.11283
Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27:1709–1718. https://doi.org/10.1007/s00198-015-3455-9
O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841. https://doi.org/10.1210/en.2003-0990
Guañabens N, Gifre L, Peris P (2014) The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis. Curr Osteoporos Rep 12:90–97. https://doi.org/10.1007/s11914-014-0197-0
Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M, Plotkin LI, Bellido T (2016) Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of sost/sclerostin. J Bone Miner Res 31:1791–1802. https://doi.org/10.1002/jbmr.2869
Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548–1558. https://doi.org/10.1016/j.clinthera.2007.08.008
Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30:1145–1156. https://doi.org/10.1007/s00198-019-04906-x
Lane NE, Yao W (2011) New insights into the biology of glucocorticoid-induced osteoporosis. IBMS BoneKEy 8:229–236. https://doi.org/10.1138/20110511
Ton FN, Gunawardene SC, Lee H, Neer RM (2004) Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20:464–470. https://doi.org/10.1359/JBMR.041125
Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A (2006) Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 17:144–149. https://doi.org/10.1016/j.tem.2006.03.009
Lespessailles E (2013) Bisphosphonates and glucocorticoid-induced osteoporosis: efficacy and tolerability. Jt Bone Spine Rev Rhum 80:258–264. https://doi.org/10.1016/j.jbspin.2012.08.005
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (2017) 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis: ACR guideline for glucocorticoid-induced osteoporosis prevention and treatment. Arthritis Rheumatol 69:1521–1537. https://doi.org/10.1002/art.40137
Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, Giusti A, Malavolta N, Minisola S, Osella G, Pedrazzoni M, Sinigaglia L, Viapiana O, Isaia GC (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 68:1–39. https://doi.org/10.4081/reumatismo.2016.870
Lekamwasam S, Agnusdei D, Bilezikian J et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276. https://doi.org/10.1007/s00198-012-1958-1
Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, Buchon D, Debiais F, Guggenbuhl P, Laroche M, Legrand E, Lespessailles E, Marcelli C, Weryha G, Thomas T, Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO) (2014) 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Jt Bone Spine Rev Rhum 81:493–501. https://doi.org/10.1016/j.jbspin.2014.10.001
Reid DM, Devogelaer J-P, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. The Lancet 373:1253–1263. https://doi.org/10.1016/S0140-6736(09)60250-6
Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF (2019) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four–month randomized, double-blind, double-dummy trial. Arthritis Rheumatol 71:1174–1184. https://doi.org/10.1002/art.40874
Saag KG, Zanchetta JR, Devogelaer J-P, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial: Teriparatide Versus Alendronate in Glucocorticoid-Induced OP. Arthritis Rheum 60:3346–3355. https://doi.org/10.1002/art.24879
Dempster DW, Roschger P, Misof BM, Zhou H, Paschalis EP, Alam J, Ruff VA, Klaushofer K, Taylor KA (2016) Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 months in the SHOTZ study: mineralization density with TPTD vs ZOL. J Bone Miner Res 31:1527–1535. https://doi.org/10.1002/jbmr.2825
Ferrari S (2009) Remodelage osseux : nouvelles approches thérapeutiques. Rev Méd Suisse 5:1325–1328
Glüer C-C, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, Farahmand P, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N, Nuti R, Martín-Mola E, Thomasius F, Kapetanos G, Peña J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial: Teriparatide and Risedronate in Gio in men in the EuroGIOPs trial. J Bone Miner Res 28:1355–1368. https://doi.org/10.1002/jbmr.1870
Takahata M, Maher JR, Juneja SC, Inzana J, Xing L, Schwarz EM, Berger AJ, Awad HA (2012) Mechanisms of bone fragility in a mouse model of glucocorticoid-treated rheumatoid arthritis: implications for insufficiency fracture risk. Arthritis Rheum 64:3649–3659. https://doi.org/10.1002/art.34639
Mellibovsky L, Prieto-Alhambra D, Mellibovsky F, Güerri-Fernández R, Nogués X, Randall C, Hansma PK, Díez-Perez A (2015) Bone tissue properties measurement by reference point indentation in glucocorticoid-induced osteoporosis. J Bone Miner Res 30:1651–1656. https://doi.org/10.1002/jbmr.2497
Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439–446. https://doi.org/10.1172/JCI6610
Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627–1633. https://doi.org/10.1172/JCI3914
Goltzman D (2008) Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys 473:218–224. https://doi.org/10.1016/j.abb.2008.03.003
Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039. https://doi.org/10.1056/NEJMoa071408
Geusens P, Marin F, Kendler DL, Russo LA, Zerbini CAF, Minisola S, Body JJ, Lespessailles E, Greenspan SL, Bagur A, Stepan JJ, Lakatos P, Casado E, Moericke R, López-Romero P, Fahrleitner-Pammer A (2018) Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial: Cdc42 in osteoarthritis. J Bone Miner Res. 33:783–794. https://doi.org/10.1002/jbmr.3384
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226. https://doi.org/10.1056/NEJMoa035725
Ettinger B, Martin SJ, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751. https://doi.org/10.1359/jbmr.040117
Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan J, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215. https://doi.org/10.1056/NEJMoa031975
Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26:503–511. https://doi.org/10.1002/jbmr.238
Achiou Z, Toumi H, Touvier J, Boudenot A, Uzbekov R, Ominsky MS, Pallu S, Lespessailles E (2015) Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia. Bone 81:691–701. https://doi.org/10.1016/j.bone.2015.09.010
Chandler H, Brooks DJ, Hattersley G, Bouxsein ML, Lanske B (2019) Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia. Osteoporos Int 30:1607–1616. https://doi.org/10.1007/s00198-019-04999-4
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw – 2009 Update. Aust Endod J 35:119–130. https://doi.org/10.1111/j.1747-4477.2009.00213.x
Albert SG, Reddy S (2017) Clinical evaluation of cost efficacy of drugs for treatment of osteoporosis: a meta-analysis. Endocr Pract 23:841–856. https://doi.org/10.4158/EP161678.RA
Murphy DR, Smolen LJ, Klein TM, Klein RW (2012) The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskelet Disord 13:213. https://doi.org/10.1186/1471-2474-13-213
Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA (2010) Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21:1041–1045. https://doi.org/10.1007/s00198-009-1004-0
Cipriani C, Irani D, Bilezikian JP (2013) Erratum: safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 28:431–431. https://doi.org/10.1002/jbmr.1837
Capriani C, Irani D, Bilezikian JP (2012) Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 27:2419–2428. https://doi.org/10.1002/jbmr.1800
Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E (2018) The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int 29:2335–2343. https://doi.org/10.1007/s00198-018-4604-8
Hagino H, Narita R, Yokoyama Y, Watanabe M, Tomomitsu M (2019) A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis. Osteoporos Int 30:2027–2037. https://doi.org/10.1007/s00198-019-05038-y
Sato D, Takahata M, Ota M et al (2020) Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats. Bone:115331. https://doi.org/10.1016/j.bone.2020.115331
Acknowledgements
The authors wish to acknowledge Kenneth G. Saag and Marie Beth Humphrey who conducted a debate on the current subject at the ACR/ARP 2019 annual meeting that inspired the writing of this position paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
E. Lespessailles received speaker and consultant fees from Abbvie, Amgen, Expanscience, Lilly, Sublimed, and UCB and research grants from Abbvie, Amgen, Lilly, MSD, and UCB. R. Chapurlat received occasional fees for interventions as an expert or speaker from Amgen, UCB, Abbvie, Pfizer, BMS, Lilly, Arrow, Medac, Mylan, Fresenius Kabi, PKMed, Biocon, Regeneron, MSD, Chugai, Sanofi, Janssen, and Kyowa Kirin
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lespessailles, E., Chapurlat, R. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first. Osteoporos Int 31, 1829–1834 (2020). https://doi.org/10.1007/s00198-020-05568-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-020-05568-w